Validation of a visual analogue score ( LRTI‐VAS ) in non‐ CF bronchiectasis

Le résumé fourni par la source

Abstract Background and Aim Quality of life in patients with non‐cystic fibrosis (non‐CF) bronchiectasis is largely defined by respiratory symptoms. To date, no disease‐specific tool for symptom measurement in this patient group was available. We developed the lower respiratory tract infections – visual analogue scale (LRTI‐VAS) in order to quickly and conveniently quantify symptoms in non‐CF bronchiectasis. This study aimed to validate LRTI‐VAS for use in non‐CF bronchiectasis. Methods This study included outpatients with radiologically proven bronchiectasis and no evidence of CF. Results of LRTI‐VAS were compared with other markers of disease activity {lung function parameters, oxygen saturation and three health‐related quality of life questionnaires [Medical Outcomes Study Short‐Form 36 Health Survey (SF‐36), St Georges Respiratory Questionnaire (SGRQ) and Leicester Cough Questionnaire (LCQ)]} and validity, reliability and responsiveness were assessed. Results Thirty stable and 30 exacerbating participants completed the LRTI‐VAS questionnaire. When testing for repeatability on two separate occasions, no statistically significant difference between total scores was found {1.4 [standard deviation (SD)] 5.3}, P = 0.16). Internal consistency was high across items (Cronbach's alpha 0.86). Correlation with SGRQ, SF‐36 and LCQ total scores was high. Following antibiotic treatment, mean (SD) LRTI‐VAS total score improved from 18.1 (SD 9.9) to 26.1 (SD 6.6) (P < 0.001). Conclusions LRTI‐VAS showed excellent validity, reliability and responsiveness to change and therefore appears a reliable tool for symptom measurement in non‐CF bronchiectasis.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.